722 reports of this reaction
2.0% of all VALGANCICLOVIR reports
#10 most reported adverse reaction
CYTOMEGALOVIRUS VIRAEMIA is the #10 most commonly reported adverse reaction for VALGANCICLOVIR, manufactured by H2-Pharma, LLC. There are 722 FDA adverse event reports linking VALGANCICLOVIR to CYTOMEGALOVIRUS VIRAEMIA. This represents approximately 2.0% of all 36,658 adverse event reports for this drug.
Patients taking VALGANCICLOVIR who experience cytomegalovirus viraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS VIRAEMIA is a less commonly reported adverse event for VALGANCICLOVIR, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus viraemia, the following adverse reactions have been reported for VALGANCICLOVIR:
The following drugs have also been linked to cytomegalovirus viraemia in FDA adverse event reports:
CYTOMEGALOVIRUS VIRAEMIA has been reported as an adverse event in 722 FDA reports for VALGANCICLOVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS VIRAEMIA accounts for approximately 2.0% of all adverse event reports for VALGANCICLOVIR, making it a notable side effect.
If you experience cytomegalovirus viraemia while taking VALGANCICLOVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.